FDA approves herbal medicine for COVID-19 clinical trial
The Food and Drugs Authority (FDA) of Ghana has approved a herbal medicine known as Cryptolepis Sanguinolenta for clinical trial on COVID-19.
A statement by the FDA said Cryptolepis Sanguinolenta which is popularly known as Nibima, has been tested in the laboratories of Kwame Nkrumah University of Science and Technology (KNUST) and has some “clinical benefits” hence its approval for clinical trials.
“It is hoped that data from this study may be useful to inform policy or be used for scientific judgments and opinions in relation to COVID-19,” the statement read in part.
Attached is the full statement:
The Ghana Medical Association (GMA) has said seven doctors have so far died of COVID-19 since it emerged in the country.
Five of the doctors died last year with two passed this year, President of the Association Dr. Frank Ankobea told Morning Starr Monday.
“The number of doctors who are getting infected is increasing. We have lost 7 of them ( 2 this year and 5 last year),” he told host Francis Abban Monday.
“We are monitoring things and if there’s the need to recommend extra restrictions to the President, trust the GMA to do that. We should embrace what the President has said as Ghanaians. We should take individual responsibility for ourselves and follow the basic rules and I’m sure we’ll be fine to go”.